Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

被引：0

作者：

Michelino De Laurentiis

Simona Borstnar

Mario Campone

Ellen Warner

Javier Salvador Bofill

William Jacot

Susan Dent

Miguel Martin

Alistair Ring

Paul Cottu

Janice Lu

Eva Ciruelos

Hamdy A. Azim

Sanjoy Chatterjee

Katie Zhou

Jiwen Wu

Lakshmi Menon-Singh

Claudio Zamagni

机构：

[1] Istituto Nazionale Tumori IRCCS “Fondazione Pascale”,Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director

[2] Institute of Oncology Ljubljana,Gregorio Marañón General University Hospital, GEICAM

[3] Western Cancer Institute,University Hospital 12 de Octubre

[4] Sunnybrook Health Sciences Centre,Faculty of Medicine

[5] Virgen del Rocío University Hospital,Duke Cancer Institute

[6] Biomedicine Institute,undefined

[7] Montpellier Cancer Institute,undefined

[8] The Ottawa Hospital Cancer Centre,undefined

[9] Universidad Complutense,undefined

[10] CIBERONC,undefined

[11] Royal Marsden Hospital NHS Foundation Trust,undefined

[12] Curie Institute,undefined

[13] USC Norris Comprehensive Cancer Center,undefined

[14] Clara Campal Comprehensive Cancer Center (HM CIOCC),undefined

[15] Cairo University,undefined

[16] Tata Medical Center,undefined

[17] Novartis Pharmaceuticals Corporation,undefined

[18] Azienda Ospedaliero-Universitaria Di Bologna,undefined

[19] Duke University School of Medicine,undefined

来源：

Breast Cancer Research and Treatment | 2022年 / 191卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：223 / 224

页数：1

共 50 条

[21] Ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
DeLaurentiis, Michelino
Neven, Patrick
Jerusalem, Guy Heinrich Maria
Bachelot, Thomas Denis
Jacot, William
Dent, Susan Faye
Colleoni, Marco
Prat, Aleix
Martin, Miguel
Ring, Alistair E.
Cottu, Paul H.
Lu, Janice M.
Azim, Hamdy A.
Zhou, Katie
Wu, Jiwen
Zarate, Juan Pablo
Zamagni, Claudio
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[22] Ribociclib (RIBO) plus letrozole (LET) in older patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial
Ring, A.
Borstnar, S.
Ferreira, A.
Azim, H. A.
Cottu, P.
Lu, J.
Martin, M.
Zamagni, C.
Beck, J. T.
Zhou, K.
Wu, J.
Menon, L.
De laurentiis, M.
CANCER RESEARCH, 2019, 79 (04)
[23] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN OLDER PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
De Laurentiis, Michelino
Campone, Mario
Alba Conejo, Emilio
Tanner, Minna
Egle, Daniel
Papai, Zsuzsanna
Prat Aparicio, Aleix
Dent, Susan
Warner, Ellen
Ankrah, Nii
Wu, Jiwen
Zhou, Katie
Borstnar, Simona
BREAST, 2019, 48 : S46 - S47
[24] First Results on Efficacy and Tolerability Phase-Ib-Study on Ribociclib (LEE011) plus Letrozole in advanced Breast Cancer
Dinkhoff, Karen
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (09) : 573 - 573
[25] Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
Takahashi, Masato
Masuda, Norikazu
Nishimura, Reiki
Inoue, Kenichi
Ohno, Shinji
Iwata, Hiroji
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Toi, Masakazu
CANCER MEDICINE, 2020, 9 (14): : 4929 - 4940
[26] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
Illiger, HJ
STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (02) : 111 - 113
[27] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group
Mouridsen, H
Gershanovich, M
Sun, Y
Pérez-Carrión, R
Boni, C
Monnier, A
Apffelstaedt, J
Smith, R
Sleeboom, HP
Jänicke, F
Pluzanska, A
Dank, M
Becquart, D
Bapsy, PP
Salminen, E
Snyder, R
Lassus, M
Verbeek, JA
Staffler, B
Chaudri-Ross, HA
Dugan, M
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2596 - 2606
[28] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, C. S.
Paluch-Shimon, S.
Campone, M.
Petrakova, K.
Blackwell, K. L.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D. A.
Mondal, S.
Su, F.
Miller, M.
Elmeliegy, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
[29] CompLEEment-1: phase 3b study of ribociclib 1 letrozole for the treatment of hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
Zamagni, C.
Martin, M.
Ring, A.
Cottu, P.
Zhou, K.
Wu, J.
Zarate, J. P.
De Laurentiis, M.
ANNALS OF ONCOLOGY, 2017, 28
[30] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
Lu, Janice
Cottu, Paul
Martin, Miguel
Zamagni, Claudio
Prat, Aleix
Chia, Stephen
Jerusalem, Guy
Rajappa, Senthil
Timcheva, Constanta
Zhukova, Lyudmila
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
De Laurentiis, Michelino
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →